 BOSTON, Sept. 01, 2022 GLOBE NEWSWIRE -- HilleVax, Inc. Nasdaq: HLVX, a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech 2022 Conference Call Series. HIL-214, HilleVaxs investigational virus-like particle VLP based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. 